Cytokines, Chemokines & Receptors

Cat. No.

A35913

CAS No.

2981430-39-9

Firsekibart

Synonyms: Genakumab; GenSci048; Kinnazumab

Firsekibart is an IgG4-λ2 monoclonal antibody that specifically targets human interleukin 1β (IL-1β). This reagent plays a critical role in studying inflammation-related diseases, including rheumatoid arthritis and inflammatory bowel disease, by modulating the IL-1β signaling pathway. Firsekibart is valuable for research applications focused on elucidating the mechanisms of inflammation and developing therapeutic strategies.

Cat. No.

A36033

CAS No.

3037526-90-9

Gimvekibart

Gimvekibart is a humanized IgG4κ monoclonal antibody that specifically targets IL-4Ra/CD124. This inhibitor is instrumental in the study of inflammatory diseases, particularly idiopathic pulmonary fibrosis (IPF). Its ability to modulate the IL-4 signaling pathway provides valuable insights for research into therapeutic strategies for various immune-mediated conditions.

Cat. No.

A36039

CAS No.

3036134-89-8

Felcorekibart

Felcorekibart is a humanized IgG1κ antibody specifically targeting thymic stromal lymphopoietin (TSLP). This antibody is vital for research into TSLP's role in immune responses, particularly in the context of allergic diseases and asthma. It is suitable for applications such as flow cytometry, ELISA, and immunohistochemistry, facilitating the study of TSLP-mediated pathways in various biological systems.

Cat. No.

A36086

CAS No.

3031358-44-5

Camtarkibart

Camtarkibart is a humanized IgG4κ antibody that targets the interleukin-4 receptor (IL4R), exhibiting immunomodulatory activity. This reagent is essential for research applications focused on immune response modulation, particularly in allergic reactions and other IL-4-mediated conditions. Its specificity for IL4R makes it a valuable tool for studying the pathways involved in Th2 responses and related immunological disorders.

Cat. No.

A36108

CAS No.

3031358-43-4

Revbekitug

Revbekitug is a humanized IgG1κ antibody that specifically targets interleukin-5 (IL-5). This antibody plays a crucial role in modulating immune responses associated with eosinophilic disorders. It is utilized in research applications focused on asthma, allergic diseases, and other conditions characterized by elevated IL-5 levels, allowing for the study of therapeutic interventions in these areas.

Cat. No.

A36116

CAS No.

2956767-43-2

Oturkibart

Synonyms: QX-005N

Oturkibart is a humanized IgG4-κ monoclonal antibody specifically targeting the human interleukin 4 receptor (IL4R). This reagent is instrumental in studies related to inflammatory diseases, including asthma and atopic dermatitis. Its targeted mechanism provides valuable insights into the role of IL4R in immune response modulation, facilitating research in therapeutic development for these conditions.

Cat. No.

A59569

CAS No.

2999644-88-9

Enzelkitug

Synonyms: RO-7502175; RG-6411

Enzelkitug is a humanized immunoglobulin G1-κ monoclonal antibody that specifically targets the C-C motif chemokine receptor 8 (CCR8). This reagent exhibits significant potential in the study of various solid tumors and hematological malignancies, enabling researchers to investigate immune response mechanisms and therapeutic strategies. Its application in immuno-oncology research could facilitate the development of targeted treatments for CCR8-expressing tumors.

Cat. No.

AT0001

Anti-TNFSF2/TNFa Antibody (hMAK195)

Synonyms: hMAK195

Anti-TNFSF2/TNFα Antibody (hMAK195) is a fully human monoclonal antibody targeting human Tumor Necrosis Factor alpha (TNFα / TNFSF2). This recombinant antibody is produced in CHO cells and features a human IgG1 heavy chain paired with a human kappa light chain. The predicted molecular weight of the intact antibody is approximately 145.06 kDa. hMAK195 is suitable for applications involving TNFα pathway modulation, including in vitro neutralization assays and preclinical research in inflammation, autoimmune disease, or cancer models.

Cat. No.

AT0004

CAS No.

2243274-14-6

Depemokimab

Synonyms: GSK-3511294

Depemokimab (GSK-3511294) is a long-acting, high-affinity human monoclonal antibody specifically targeting interleukin-5 (IL-5), a key cytokine involved in the proliferation, activation, and survival of eosinophils. Engineered for extended half-life and sustained biological activity, Depemokimab is designed to enable infrequent dosing while maintaining effective IL-5 pathway blockade. This antibody is a valuable tool for preclinical research in eosinophilic asthma and other IL-5–mediated inflammatory diseases. Its pharmacokinetic and immunomodulatory properties make it suitable for evaluating long-term IL-5 inhibition in both in vitro and in vivo models.

Cat. No.

AT0010

CAS No.

2991369-43-6

Dalidnetug

Dalidnetug is a humanized monoclonal antibody designed to selectively bind growth differentiation factor 15 (GDF-15), a member of the TGF-β superfamily associated with stress response, cancer progression, and metabolic regulation. This antibody enables research into GDF-15-mediated signaling pathways and is suitable for use in preclinical studies of oncology, cardiovascular disorders, and inflammation.

Cat. No.

AT0011

CAS No.

2484883-56-7

Eltrekibart

Eltrekibart is a human IgG4κ monoclonal antibody that targets CXCL chemokines, key mediators involved in leukocyte trafficking and inflammatory responses. By modulating CXCL-related pathways, Eltrekibart serves as a useful tool for investigating chronic inflammation, immune cell migration, and chemokine-receptor signaling in disease models. Recommended isotype control: Human IgG4 (S228P) kappa isotype control.

Cat. No.

AT0024

CAS No.

879293-15-9

Ordesekimab

Synonyms: AMG 714; PRV-015

Ordesekimab is a fully human IgG1κ monoclonal antibody that targets interleukin-15 (IL-15). It blocks the interaction of IL-15 with the IL-2Rβ and common γ chain components of the IL-15 receptor complex, without affecting binding to IL-15Rα. Ordesekimab is a valuable tool for studying IL-15–driven immune responses and is under investigation for use in nonresponsive celiac disease (NRCD).

Cat. No.

AT0028

Anti-CXCL9 Antibody

Anti-CXCL9 is a humanized IgG1κ monoclonal antibody expressed in CHO cells, specifically targeting the chemokine CXCL9. This antibody is used in inflammation and tumor immunology research, particularly in contexts involving chemokine-mediated immune cell recruitment. Recommended isotype control: Human IgG1 kappa isotype control.

Cat. No.

AT0043

CAS No.

2770858-49-4

Lunsekimig

Lunsekimig is a multispecific monoclonal antibody comprising five tandemly linked variable heavy chain domains that target thymic stromal lymphopoietin (TSLP), interleukin-13 (IL-13), and albumin (ALB). This engineered format offers enhanced functionality and half-life extension and is used in research on allergic inflammation and respiratory diseases such as asthma.

Cat. No.

AT0045

CAS No.

2428381-56-8

Manfidokimab

Synonyms: AK120

Manfidokimab (AK120) is a human IgG4 monoclonal antibody targeting the interleukin-4 receptor alpha (IL-4Rα), a shared subunit of the IL-4 and IL-13 receptors. By inhibiting IL-4Rα signaling, Manfidokimab modulates type 2 inflammation and is used in research on asthma, atopic dermatitis, and other allergic conditions.

Cat. No.

AT0046

CAS No.

2762183-23-1

Bosakitug

Bosakitug is a humanized IgG1κ monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), a cytokine involved in allergic and epithelial-driven inflammation. This antibody is suitable for preclinical models of asthma, chronic rhinosinusitis, and other type 2 immune disorders. Recommended isotype control: Human IgG1 kappa isotype control.

Cat. No.

AT0049

CAS No.

2744274-11-9

Betinukibart

Betinukibart is a human IgG1κ monoclonal antibody targeting interleukin-17A (IL-17A), a pro-inflammatory cytokine involved in autoimmune and inflammatory diseases. This antibody is used in preclinical research on IL-17–mediated pathways in conditions such as psoriasis, ankylosing spondylitis, and rheumatoid arthritis. Recommended isotype control: Human IgG1 kappa isotype control.

Cat. No.

AT0052

CMAB008

CMAB008 is a monoclonal antibody specifically targeting tumor necrosis factor alpha (TNFα), a cytokine involved in systemic inflammation and a key player in autoimmune disorders such as rheumatoid arthritis (RA). This antibody has therapeutic potential in modulating immune responses and alleviating symptoms associated with RA. CMAB008 represents a promising tool for both basic research and clinical applications in the study and treatment of inflammatory diseases.

Cat. No.

AT0057

ABX-IL8

ABX-IL8 is a human-derived monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the chemokine CXCL8/IL-8. This antibody is comprised of a human IgG2 heavy chain and a human kappa light chain, with a predicted molecular weight of approximately 143.94 kDa. For isotype control purposes, Human IgG2 kappa, Isotype Control is recommended. ABX-IL8 is suitable for use in various immunological assays that require precise interaction with its target, making it an essential tool for research in inflammation, immune response, and related pathological conditions.

Cat. No.

AT0065

PF-06342674

PF-06342674 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the interleukin-7 receptor alpha (IL-7Ra), also known as CD127. This antibody is comprised of a human IgG1 heavy chain and a human lambda light chain, with an estimated molecular weight of 145.14 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa. PF-06342674 is applicable for use in various immunological assays to study the role of IL-7Ra in immune function and development.

Cat. No.

AT0073

CAS No.

2923284-76-6

Lecankitug

Lecankitug is a humanized monoclonal antibody engineered to selectively target and neutralize both interleukin 17A (IL-17A) and interleukin 17F (IL-17F). By binding to these cytokines, Lecankitug effectively inhibits their signal transduction pathways, resulting in pronounced immunosuppressive and anti-inflammatory effects. This antibody is particularly valuable for research into the pathogenesis and potential treatment strategies for autoimmune and inflammatory disorders, including psoriasis and rheumatoid arthritis.

Cat. No.

AT0090

CAS No.

1044515-88-9

Tralokinumab

Synonyms: CAT354

Tralokinumab (CAT354) is a humanized IgG4 monoclonal antibody engineered to bind specifically to interleukin-13 (IL-13), effectively neutralizing its activity. This antibody is extensively utilized in the study of diseases characterized by IL-13 involvement, including asthma, atopic dermatitis, and pulmonary fibrosis. Tralokinumab's targeted mechanism of action and specificity for IL-13 make it a valuable tool in immunological and inflammatory research contexts.

Cat. No.

AT0093

CAS No.

162774-06-3

Nerelimomab

Synonyms: BAYX1351

Nerelimomab (BAYX1351) is a monoclonal antibody targeting tumor necrosis factor-alpha (TNF-α). This antibody is specifically designed for use in research studies investigating the pathophysiology and potential therapeutic interventions for sepsis. By inhibiting TNF-α, Nerelimomab serves as a valuable tool for elucidating the role of this cytokine in inflammatory responses and its impact on sepsis progression.

Cat. No.

AT0097

HFB-200301

HFB-200301 is a monoclonal IgG1 antibody specifically designed to target tumor necrosis factor receptor 2 (TNFR2). This antibody facilitates the activation of TNFR2, which in turn initiates the classical NF-κB signaling pathway, involving the activation of RelA and cRel-containing NF-κB dimers. This activation impacts cellular metabolism and gene expression in response to soluble TNF (sTNF). HFB-200301 holds significant potential for advancing research in cancer biology, particularly in studies exploring the molecular mechanisms of TNFR2 in tumor progression and immune responses.

Cat. No.

AT0102

CAS No.

2956768-50-4

Crusekitug

Crusekitug is a humanized monoclonal antibody that selectively targets human interleukin 17A (IL-17A). By specifically binding to IL-17A, Crusekitug impedes its signal transduction pathways, thereby exhibiting immunosuppressive and anti-inflammatory effects. This antibody is particularly valuable for research into autoimmune and inflammatory disorders, including psoriasis and rheumatoid arthritis, offering insights into disease mechanisms and potential therapeutic interventions.